Peptide Synthesis Market Outlook:
Peptide Synthesis Market size was over USD 5.8 billion in 2025 and is estimated to reach USD 12.2 billion by the end of 2035, expanding at a CAGR of 8.7% during the forecast timeline, i.e., 2026-2035. In 2026, the industry size of peptide synthesis is estimated at USD 6.3 billion.
The worldwide peptide synthesis market is steadily growing and readily supported by a rise in the adoption of peptide-driven therapeutics, research applications, and diagnostics. Besides, peptides have been recognized for their versatility, safety, and specificity, particularly in aiding oncological, cardiovascular, and metabolic diseases. According to an article published by NLM in May 2025, therapeutic peptides, with a molecular weight ranging between 50 to 5,000 Da, outstandingly bridge the barrier between biologics and small molecules through their multifaceted biointerfaces and programmable architectures. Besides, more than 80 peptide drugs have successfully gained international approval as of 2023, with over 200 peptides in clinical development. These particular peptides are focused on cancers, metabolic disorders, autoimmune diseases, and infectious diseases, thus proliferating the market’s exposure.
FDA-Approved and Clinical-Trial Therapeutic Peptides for Aiding Different Pathologies (2025)
|
Disease Type |
FDA-based Peptides |
Clinical Trial-Based Peptides |
|
Metabolic Disorder |
37% |
23% |
|
Cancer |
19% |
35% |
|
Cardiovascular Disorder |
11% |
6% |
|
Antibacterial |
10% |
5% |
|
Gastrointestinal Disorders |
10% |
6% |
|
Pain Management |
5% |
- |
|
Central Nervous System Disorder |
3% |
22% |
|
Respiratory Disorders |
2% |
3% |
|
Renal Disorders |
2% |
- |
|
Others |
1% |
- |
Source: International Journal of Pharmaceuticals
Furthermore, the aspects of high-throughput and automation synthesis, expansion in customized peptide services, integration of digitalized and artificial intelligence tools, green chemistry and sustainability adoption, and diversification into non-pharma applications are other drivers that are fueling the peptide synthesis market globally. In terms of automation, Syngene International, as of October 2025, declared site upgradation to escalate drug discovery as well as development for assisting its consumers to introduce notable therapies to the peptide synthesis market rapidly. This included a state-of-the-art and dedicated peptide laboratory in Bengaluru, comprising cyclic peptides, linear peptides, and peptide-drug conjugates, and readily supports scale for almost 800 mmol. Likewise, in April 2025, Sai Life Sciences Limited successfully inaugurated a standard peptide research center at Hyderabad for supporting biotech organizations and innovative pharmacies with specialized services across peptide synthesis.
